Yes it is amazing what can be accomplished when a biotech has the financial support it needs to succeed. As Alan pointed out in his AGM speech, it has been a long journey for CU6 to get to this point (2012), but now we are here the outlook is very promising. I hope CU6 get to finish line and are not gobbled up cheaply.
Ann: First patient dosed in Phase III prostate cancer trial, page-6
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.67 |
Change
-1.060(12.1%) |
Mkt cap ! $2.451B | |||
| Open | High | Low | Value | Volume |
| $8.62 | $8.68 | $7.67 | $13.44M | 1.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21192 | $7.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.72 | 59 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |